Calcium ketovaline as new therapy for uremic hyperphosphatemia.
Since treatment of uremic hyperphosphatemia still represents a major problem and phosphate-binding agents carry the well-known risk of aluminum intoxication, we carried out a study to determine whether calcium ketovaline, a keto acid containing calcium, would show phosphate-binding effects comparable to those obtained with a mixture of amino acids and calcium salts of ketoanalogues tested previously. In vitro as well as in vivo studies show convincingly that calcium ketovaline is a valuable intestinal phosphate binder. Dialysis patients treated for 6 weeks showed a significant (p less than 0.05) decrease in serum phosphate from 2.36 +/- 0.19 to 1.81 +/- 0.16 mmol/l.
Schaefer
K
K
Medizinische Abteilung II, St. Joseph-Krankenhaus I, Berlin.
von Herrath
D
D
Erley
C M
CM
Asmus
G
G
D045782:Hemiterpenes; D006801:Humans; D066298:In Vitro Techniques; D007651:Keto Acids / Q000627:therapeutic use*; D010710:Phosphates / Q000097:blood*; D006435:Renal Dialysis; D014511:Uremia / Q000150:complications / Q000188:drug therapy*
D045782:Hemiterpenes; D007651:Keto Acids; D010710:Phosphates; C001505:alpha-ketoisovalerate